6.2.1.2.4. active surveillance management. based detective consensus study, surveillance strategy based serial dre (at least yearly), psa (at least once, every six months) repeated biopsy. also agreed psa progression change psa kinetics alone lead reclassification accompanied changes histology repeat biopsy . movember consensus group stated patients suitable suffer, risk of, significant psychological distress offered support, rather active treatment. furthermore, made number recommendations ways differ detective consensus study, e.g. routine dre supported mri imaging carried routinely as, mri parameters (psa kinetics density) stable routine biopsy may omitted change clinical parameters prompt mri possible biopsy rather immediate biopsy . somewhat contradicting recommendations, made two different international consensus groups close time, clearly illustrate lack high-level evidence strategy planned urgent need prospective randomised trials. 2016, prostate cancer radiological estimation change sequential evaluation (precise) criteria established standardise assessment tumour progression serial mri . progression mri, not, defined precise criteria, strong predictor histological upgrading . two independent meta-analyses assessed value mri progression criteria predicting histological progression (mostly defined progression isup grade group â‰¥ 2). pooled histological progression rate 27% reviews. biopsies triggered mri progression findings, approximately two thirds biopsies would avoided, cost missing 40% men histological progression. addition, least half biopsied men would negative findings histological progression thus would undergone unnecessary biopsies. histological progression restricted progression isup grade group > 3, approximately 30% histological progression would missed approximately 80% biopsies performed would unnecessary. use precise criteria seem change results . supports maintaining protocol-mandated repeat biopsies course as. thus, basis protocols includes standard repeat biopsy. however, several factors found associated low re-classification rates long pfs: negative baseline repeat mri [505,512-518], low psa-d , low psa velocity (psav) negative biopsy (i.e., cancer all) confirmatory repeat biopsy . patients stable (precise 3) repeat mri low psa-d (<0.15) low rate progression repeat biopsy may therefore omitted . panel sr incorporating 263 surveillance protocols showed 78.7% protocols mandated per-protocol confirmatory biopsies within first two years 57.7% protocols performed repeat biopsy least every three years ten years start . another review concluded negative repeat biopsy associated 50% decrease risk future reclassification upgrading . single-centre cohort 514 patients underwent least three protocol-mandated biopsies diagnosis (the confirmatory biopsy least two additional surveillance biopsies), men one negative biopsy (i.e., cancer all) confirmatory second biopsy, men two consecutive negative biopsies lower likelihood positive third biopsy significantly better 10-year treatment free survival . suggests men repetitive negative biopsies may pursue least less frequent untriggered biopsies.